Your browser doesn't support javascript.
loading
Copeptin as a marker of an altered CRH axis in pituitary disease.
Lewandowski, Krzysztof C; Lewinski, Andrzej; Skowronska-Józwiak, Elzbieta; Malicka, Katarzyna; Horzelski, Wojciech; Brabant, Georg.
Affiliation
  • Lewandowski KC; Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.
  • Lewinski A; Polish Mother's Memorial Hospital-Research Institute, Lodz, Poland.
  • Skowronska-Józwiak E; Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.
  • Malicka K; Polish Mother's Memorial Hospital-Research Institute, Lodz, Poland.
  • Horzelski W; Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.
  • Brabant G; Polish Mother's Memorial Hospital-Research Institute, Lodz, Poland.
Endocrine ; 57(3): 474-480, 2017 Sep.
Article in En | MEDLINE | ID: mdl-28795329
BACKGROUND: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone. PATIENTS AND METHODS: Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test. RESULTS: Patients with previous pituitary disease were subdivided in a group passing the test (P1, n = 20) and failing (P2, n = 9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p = 0.04 for P1 + P2) with a maximum increase in controls from 3.84 ± 2.86 to 12.65 ± 24.87 pmol/L at 30 min, p < 0.05. In contrast, both groups of pituitary patients lacked a significant copeptin response to corticotrophin-releasing hormone, and even in P1, where adrenocorticotropin concentrations increased fourfold (mean, 21.48 vs. 91.53 pg/mL, p < 0.01), copeptin did not respond (e.g., 4.35 ± 5.81 vs. 5.36 ± 6.79 pmol/L, at 30 min, p = ns). CONCLUSIONS: Corticotrophin-releasing hormone is able to stimulate copeptin release in healthy controls suggesting a direct interaction of corticotrophin-releasing hormone and vasopressin/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard corticotrophin-releasing hormone test indicating (1) the corticotrophin-releasing hormone-adrenocorticotropin-cortisol response is largely independent from the vasopressin system, but (2) the corticotrophin-releasing hormone-vasopressin interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Diseases / Pituitary Gland / Corticotropin-Releasing Hormone / Glycopeptides / Signal Transduction / Receptors, Corticotropin-Releasing Hormone / Hypothalamo-Hypophyseal System Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Endocrine Journal subject: ENDOCRINOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Diseases / Pituitary Gland / Corticotropin-Releasing Hormone / Glycopeptides / Signal Transduction / Receptors, Corticotropin-Releasing Hormone / Hypothalamo-Hypophyseal System Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Endocrine Journal subject: ENDOCRINOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication: